Home
Refresh   Tag(s): ; ; ; ; ; ; ; ; ;
Add to My Group
May 22, 2006 at 15:54:14

View Ratings | Rate It

Merck Litigation Strategy - Destroy Expert Witnesses

submit to twitter
submit to reddit
submit to digg
Tell A Friend

By Evelyn Pringle (about the author)     Page 9 of 11 page(s)

opednews.com     Permalink

Dr Topol, testified that 3 years before the drug was pulled off the market, he and two colleagues published a paper in the Journal of the American Medical Association that raised the issue of whether Vioxx caused heart problems.

Dr Topol pointed out that although they published clear warnings about the cardiovascular risk in 2001, the FDA never ordered a trial to determine the extent of the problem and said Merck countered the JAMA article with a "relentless series of publications" and numerous papers in peer-reviewed medical literature written by Merck employees and consultants.

During his testimony, Dr Topol told the jury how a colleague at the Cleveland Clinic, Richard Rudick, had informed him that Raymond Gilmartin, the former CEO of Merck, had called the Cleveland Clinic board of trustees and complained about Dr Topol in mid-October 2004, after he criticized Merck's handling of the Vioxx situation in the New York Times and New England Journal of Medicine.

He described how Mr Gilmartin called the chairman of the board, and said "what has Merck ever done to the Cleveland Clinic to warrant this?'


Dr Topol told the jury that Mr Gilmartin's approach "appalled" him.

Two days after his deposition was played in court, Dr Topol found himself removed as provost and chief academic officer at the Cleveland Clinic medical school.

According to Dr Topol, he was told early in the morning not to attend a meeting of the clinic's board of governors, because the position of chief academic officer had been abolished.

Dr Tope was somewhat vindicated later in December 2005, with the publication of an "Expression of Concern" by the editors of the New England Journal of Medicine, that charged that the VIGOR, published in the journal in 2000, was submitted to the journal after data on 3 heart attacks and other cardiovascular events among trial participants was deleted by Merck.

According to an article by Amanda Gardner in Health Day Reporter, right after Vioxx was removed from the market, the editors opened a computer diskette that had been submitted with the study and found a blank table with no data - lines had been drawn but not filled in.

"They did not know what should have been in there," Sandra Jacobs, a spokeswoman for the NEJM said. "It raised some concern, but we didn't know enough to act on it," Jacobs added.

On November 21, 2005, Ms Garner says, NEJM's executive editor, Dr Gregory Curfman, was deposed for a Vioxx trial and during the process, a July 5, 2000 memorandum came to light that indicated that at least 2 of the VIGOR authors knew of the problems 2 weeks before submitting the first of two revisions, and four-and-a-half months before the study was actually published.

Dr Curfman told HealthDay that electronic records showed "a pre-submission version of the study from which data, including the number of heart attacks and deaths, were deleted by a Merck editor two days before submission."

As a dedicated scientist and health practitioner with nothing to gain, in hindsight, it appears that Dr Topol certainly paid a high price for committing the simple act of truth-telling to protect the public from a dangerous drug and its pusher.

As a small law firm practitioner turned legal reform activist, Attorney Zena Crenshaw is highly critical of Merk's debilitating cross examinations of experts who essentially claim the company recognized Vioxx's potential cardiac risks before it went on the market.

Ms Crenshaw is the Executive Director for National Judicial Conduct and Disability Law Project, Inc, a legal reform organization combating abuses of the American legal system that are facilitated by judicial misconduct.

She explains that such is a signature tactic of "mega-corporations" that it seems only "mega-lawfirms" and governmental agencies can neutralize.

Next Page  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11

 

Evelyn Pringle is a columnist for OpEd News and investigative journalist focused on exposing corruption in government and corporate America.

The views expressed in this article are the sole responsibility of the author
and do not necessarily reflect those of this website or its editors.

Contact Author Contact Editor View Authors' Articles

 

Book Recommendations for "Corporate Accountability"
Corporate Governance and Accountability
by Jill Solomon

$68.95
Lowest New Price $29.75

Number of pages: 402
Publisher: Wiley

Corporate Accountability in International Environmental Law
by Elisa Morgera

$130.00
Lowest New Price $97.11

Number of pages: 300
Publisher: Oxford University Press, USA

The New Corporate Accountability: Corporate Social Responsibility and the Law

$65.00
Lowest New Price $53.34

Number of pages: 602
Publisher: Cambridge University Press

Counting What Counts: Turning Corporate Accountability to Competitive Advantage
by Marc J. Epstein

$18.50
Lowest New Price $1.89

Number of pages: 320
Publisher: Basic Books

View All Book Recommendations

Share this page: (what's this?)                   Tell a Friend: Tell A Friend

FACEBOOK      DIGG THIS      Add This Page to Mr Wong!           NEWSVINE      DEl.ICIO.US      Looksmart Furl      NETSCAPE      My Web      Tag!RawSugar      Blink List     (More...)

Comments: Expand   Shrink   Hide  
No comments

 
Want to post your own comment on this Article? Post Comment


 

 

 

Tell a Friend: Tell A Friend

Copyright © 2002-2009, OpEdNews

Powered by Populum